Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (Resovist ): New protocol infusion to improve arterial phase evaluation-A prospective study

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 3, 2009, Pages 607-616

  Grazioli, Luigi ^a,d   Bondioni, Maria Pia ^b   Romanini, Laura ^a   Frittoli, Barbara ^a   Gambarini, Sebastiana ^a   Donato, Francesco ^b   Santoro, Lucia ^c   Colagrande, Stefano ^c  

^a Department of Radiology   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d SPEDALI CIVILI   (Italy)

Author keywords

Contrast media; Dynamic MR imaging; feruca rbotran; liver MRI; RESOVIST ; Superparamagnetic iron oxide (SPIO)

Indexed keywords

FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; IRON; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; OXIDES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 63449118021     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21644     Document Type: Article

References (17)

1. Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P. Contrast-enhanced blood-pool MR Angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 2002;223:432-438.
2. Marin D, Iannaccone R, Laghi A, et al. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2007;25:775-782.
3. Lencioni R, Della Pina C, Bruix J, et al. Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. Dig Dis Sci 2005;50:533-537.
4. Reimer P, Balzer T. Ferucarbotran (RESOVIST®): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and application. Eur Radiol 2003;13:1266-1276.
5. Park Y, Choi D, Kim SH, et al. Changes in signal-to-noise ratios and contrast-to-noise ratios of hypervascular hepatocellular carcinomas on ferucarbotran-enhanced dynamic MR imaging. Eur J Radiol 2006;59:424-431.
6. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998;8:1198-1204.
7. Chen F, Ward J, Robinson PJ. MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superpara-magnetic iron oxide agents. Magn Reson Imaging 1999;17:549-556.
8. Bloembergen N. Proton relaxation times in paramagnetic solutions,J Chem Phys 1957;27:572.
9. Solomon I. Relaxation processes in a system of two spins. Physiol Rev 1955;99:559.
10. Schnorr J, Wagner S, Abramjuk C, et al. Focal liver lesions: SPIO, gadolinium, and ferucarbotran-enhanced dynamic T1 weighted and delayed T2-weighted MR imaging in rabbits. Radiology 2006;240:90-100.
11. Wersebe A, Wiskirchen J, Decker U, et al. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Invest Radiol 2006;41:264-271.
12. Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium-and superparamagnetic iron oxide-enhanced T1 weighted MR imaging. Radiology 2005;237:520-528.
13. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons; 1981. p 165-168.
14. Altman DG. Practical statistics for medical research. London:Chapman and Hall; 1991. p 403-409.
15. Namkung S, Zech CJ, Heimberger T, Reiser MF, Schoenberg SO. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007;25:755-765.
16. Masatoshi H, Murakami T, Kim T, et al. Hemodynamic characterization of focal hepatic lesions: role of ferucarbotran-enhanced dynamic MR imaging using T2-weighted multishot spin-echo echo-planar sequences. J Magn Reson Imaging 2006;23:509-519.
17. Josephson L, Lewis J, Jacobs P. The effect of iron oxides on proton relaxivity. Magn Reson Imaging 1988;6:647-653.